Synthesis and properties of 2-S-(N,N-dialkylamino)ethyl)thio-1,3,2-dioxaphosphorinane 2-oxide and of the corresponding quaternary derivatives as potential nontoxic antiglaucoma agents.

A new series of cyclic organophosphorus esters, 2-S-[2'-N,N-dialkylamino)ethyl]thio-1,3,2-dioxaphosphorinane 2-oxide and their quaternary derivatives, was synthesized and studied as potential antiglaucoma agents. Thes compounds inhibit acetylcholinesterase (E.C. a bimoecular rate constant (ki) in the range of 10(3)-10(4) M-1 min-1. Values of the affinity (K) and phosphorylation (k') rate constants for this enzyme indicate that k' is responsible for the relatively low values of ki as compared with similar data for the open-chain analogues, O,O-diethyl phosphorothiolates (10(6) M-1 min-1). The mammalian toxicity of the new compounds in terms of acute LD50 values in mice is 1-3 x 10(3) less than that of phospholine, an open-chain analogue. In an initial clinical trial, one member of the new series (alkyl = C2H5) caused a significant decrease of intraocular pressure in aphakic glaucoma, while phospholine proved to be ineffective.
AuthorsG Amitai, Y Ashani, Y Grunfeld, A Kalir, S Cohen
JournalJournal of medicinal chemistry (J Med Chem) Vol. 19 Issue 6 Pg. 810-3 (Jun 1976) ISSN: 0022-2623 [Print] UNITED STATES
PMID950651 (Publication Type: Journal Article)
Chemical References
  • Cholinesterase Inhibitors
  • Onium Compounds
  • Phosphoranes
  • Animals
  • Cholinesterase Inhibitors
  • Eels
  • Electric Organ (enzymology)
  • Female
  • Glaucoma (drug therapy)
  • Kinetics
  • Lethal Dose 50
  • Mice
  • Onium Compounds (chemical synthesis, pharmacology, toxicity)
  • Phosphoranes (chemical synthesis, pharmacology, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: